ArticleFrontiers in veterinary science2026
Treatment of canine otitis externa: a randomized, double-blinded, clinical field study comparing the hydrocortisone aceponate monotherapy to a multi-agent reference product.
Article in Frontiers in veterinary science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Erythemato-ceruminous otitis externa (ECOE) is a canine inflammatory condition very frequently involving secondary microbial infections. This multicentric, masked, randomized, clinical field trial in Japan evaluated the efficacy and safety of a hydrocortisone aceponate (HCA) spray solution (Cortotic™, Virbac, France) compared to a terbinafine/florfenicol/betamethasone acetate ear gel (Osurnia™, Bussan Animal Health CO Ltd, Japan) in 200 dogs with ECOE (OTIS3 ≥ 5). Dogs received either Cortotic™ daily for 7 or 14 days or Osurnia™ on Days 0 and 7. OTIS3 clinical evaluation and cytological examinations were conducted, as well as the subjective veterinarian product efficacy evaluation. Results showed no significant differences between groups in OTIS3 score reduction, cytological reduction, or treatment success rates at any time point. On Day 28, Cortotic™ showed a 72.1% OTIS3 reduction, comparable to Osurnia™ 76.1%. Treatment success rates were also similar, and relapse rate was low in both groups. On Day 28, the veterinarians subjectively assessed the efficacy as good or excellent in 83% of cases for Cortotic™ and 87% for Osurnia™. Both treatments were well-tolerated. Cortotic™ demonstrated non-inferiority to Osurnia™ regarding clinical and cytological efficacy. The use of Cortotic™, a corticosteroid-monotherapy, can offer an effective strategy for managing ECOE while avoiding unnecessary antibiotic exposure. This study supports Cortotic™ as a first-line therapeutic option for otitis externa in dogs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.